JSJ Pharmaceuticals

Cipher Pharmaceuticals is a specialty pharmaceutical company dedicated to improving the health and wellbeing of patients by providing best-in-class products for unmet medical needs. Our robust and diversified portfolio spans various stages of commercialization, from early to late-stage products, ensuring we can make a significant impact on patients' lives. Cipher operates with a lean corporate structure and strategic operational partnerships, enabling us to manage the clinical development and regulatory approval process efficiently. We also in-and out-license products and make selective investments in drug development, further expanding our portfolio of prescription products.

Our Team

Cipher's team is composed of seasoned professionals with decades of experience and a proven track record of success in all facets of dermatology product development and commercialization. Our team's unwavering dedication to our vision has been instrumental in expanding our product offerings and presence in North America.

*Craig Mull, Interim Chief Executive Officer*

Craig Mull brings a wealth of experience to Cipher, having played a pivotal role in building CML Healthcare from a $20 million annualized revenue to over $235 million and its successful launch as a public company. Additionally, Craig is the CEO and founder of Typhon Group Ltd., a real estate development firm. His Honours Business Administration (HBA) from Ivey Business School at the University of Western Ontario has equipped him with the knowledge and skills necessary to lead Cipher towards continued success.

*Bryan Jacobs, Chief Financial Officer*

Bryan Jacobs is a seasoned financial leader with extensive experience in pharmaceutical, healthcare, and automation industries. Throughout his career, he has led businesses to receive Best Managed Company awards, demonstrating his expertise in Canadian and U.S. capital markets, business development, and strategic M&A. Bryan holds an Honours Bachelor of Commerce (BCom) from McMaster University and a CPA, CA designation, making him a valuable asset to our team.

*Karen vonZitzewitz, Chief Business Officer*

Karen vonZitzewitz is a visionary commercial executive with a diverse range of experiences in sales, marketing, and global development teams at Eli Lilly, GSK, and Roche. She has spent the latter part of her career in Business Development roles with start-ups and small biotech companies in Canada and the US. Her dual Honours Bachelor of Science and Bachelor of Arts degree with a minor in Health Sciences from Queen's University, Canada, has provided her with a strong foundation for her role at Cipher.

*Ryan Mailling, Vice President, Finance*

Ryan Mailling has held progressive finance roles in pharmaceutical, manufacturing, and automation industries. His experience in these sectors makes him a valuable addition to the Cipher team. Ryan has a Bachelor of Commerce degree from the University of Guelph, further solidifying his expertise in financial management.

Products and Services

Cipher Pharmaceuticals is committed to developing and acquiring best-in-class products for unmet medical needs. We manage the clinical development and regulatory approval process for our products, ensuring they meet the highest standards of quality and safety. Our portfolio includes commercial products and early to late-stage products, which we market directly in Canada and indirectly through partners in the U.S. and South America.

Our services include:

1. Product Development: We develop and acquire products that fulfill unmet medical needs, ensuring the best possible outcomes for patients.

2. Clinical Development and Regulatory Approval: We manage the clinical development and regulatory approval process for our products, ensuring they meet the stringent requirements for quality and safety.

3. Marketing and Distribution: We market our products directly in Canada and indirectly through partners in the U.S. and South America, ensuring patients have access to the best-in-class products they need.

4. Operational Partnerships: We employ strategic operational partnerships, in-and out-licensing products, and making selective investments in drug development to assemble a broad portfolio of prescription products.